Lu Miao*, Li Jing, Buze Chen, Tian Zeng and Youguo Chen Pages 1 - 13 ( 13 )
Background: Some tumors have a poor prognosis regarding TPD52 (tumor protein D52). This study aims to explore TPD52's role in the cancer process from a pan-cancer perspective. <p> Methods: A pan-cancer analysis was conducted to investigate how TPD52 may be involved in cancer as well as its association with prognosis. <p> Results: A variety of human cancers express TPD52 abnormally and correlate with clinical stage. There was a significant association between low expression of TPD52 and poor survival in BRCA, KIRP, LAML, LIHC, UCEC, and UVM. TPD52 alterations were most frequently amplified in pan-cancer. The co-occurrence of 10 genes alterations was found in the TPD52 altered group. There was a significant association between TPD52 expression and MSI in four cancer types and TMB in twelve cancer types. There was a significant correlation between TPD52 expression and immunerelated cell infiltration. A significant correlation was found between TPD52 expression in many tumor types and 8 immune checkpoint genes. There were signaling pathways involved in pan-cancer caused by TPD52, including endocytosis, Fc gamma Rmediated phagocytosis, and so on. TPD52 may be involved in chemotherapy and chemoresistance. <p> Conclusion: The TPD52 gene may be important for human cancer treatment.
Pan cáncer, TPD52, prognosis, immune infiltration, drug sensitivity, genomic alteration.